153 related articles for article (PubMed ID: 24068579)
1. A novel, cell-free PCR-based assay for evaluating the inhibitory activity of antiretroviral compounds against HIV reverse transcriptase.
Frezza C; Balestrieri E; Marino-Merlo F; Mastino A; Macchi B
J Med Virol; 2014 Jan; 86(1):1-7. PubMed ID: 24068579
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of a simple and effective RT-qPCR inhibitory assay for detection of the efficacy of compounds towards HIV reverse transcriptase.
Marino-Merlo F; Frezza C; Papaianni E; Valletta E; Mastino A; Macchi B
Appl Microbiol Biotechnol; 2017 Nov; 101(22):8249-8258. PubMed ID: 28963576
[TBL] [Abstract][Full Text] [Related]
3. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
Vázquez-Rosales G; García Lerma JG; Yamamoto S; Switzer WM; Havlir D; Folks TM; Richman DD; Heneine W
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1191-200. PubMed ID: 10480632
[TBL] [Abstract][Full Text] [Related]
4. Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
Aguiar RS; Costa LJ; Pereira HS; Brindeiro RM; Tanuri A
Antimicrob Agents Chemother; 2007 Feb; 51(2):638-44. PubMed ID: 17116672
[TBL] [Abstract][Full Text] [Related]
5. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
7. Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay.
Munshi V; Lu M; Felock P; Barnard RJ; Hazuda DJ; Miller MD; Lai MT
Anal Biochem; 2008 Mar; 374(1):121-32. PubMed ID: 17964275
[TBL] [Abstract][Full Text] [Related]
8. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
Cao YL; Li SX; Chen H; Guo Y
Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
[TBL] [Abstract][Full Text] [Related]
9. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
10. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
11. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
12. Identification of HIV-1 reverse transcriptase inhibitors using a scintillation proximity assay.
Van Schoubroeck B; Van Loock M; Ivens T; Dehertogh P; Jochmans D; Dams G
Methods Mol Biol; 2013; 1030():19-24. PubMed ID: 23821257
[TBL] [Abstract][Full Text] [Related]
13. Identification of anti-HIV and anti-reverse transcriptase activity from Tetracera scandens.
Kwon HS; Park JA; Kim JH; You JC
BMB Rep; 2012 Mar; 45(3):165-70. PubMed ID: 22449703
[TBL] [Abstract][Full Text] [Related]
14. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
Hazen RJ; Harvey RJ; St Clair MH; Ferris RG; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Romines KR; Chan JH; Boone LR
Antimicrob Agents Chemother; 2005 Nov; 49(11):4465-73. PubMed ID: 16251284
[TBL] [Abstract][Full Text] [Related]
15. FRET-based assay to screen inhibitors of HIV-1 reverse transcriptase and nucleocapsid protein.
Sharma KK; Przybilla F; Restle T; Godet J; Mély Y
Nucleic Acids Res; 2016 May; 44(8):e74. PubMed ID: 26762982
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
18. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
20. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation.
Tachedjian G; Moore KL; Goff SP; Sluis-Cremer N
FEBS Lett; 2005 Jan; 579(2):379-84. PubMed ID: 15642347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
